EUVIMEDEUVIMED entdecken
Crossref

Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease

Sadegh Salarinasab, Afsaneh Asgari Taei, Neda Kaveh, Saeed Karima, Abdolrahim Nikzamir, Leila Dargahi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04545-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Sadegh Salarinasab und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Insulin, tau Proteins, Alzheimer Disease, Phenylurea Compounds. Die Arbeit nennt 43 Literaturangaben. Gefördert von: The authors declare that this study was funded by the Research Affairs of Shahid Beheshti University of Medical Sciences..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Alzheimer's disease (AD), often described as "type 3 diabetes" due to its metabolic and neuroendocrine features, is marked by impaired glucose metabolism and insulin signaling. This study aimed to investigate whether regorafenib, a multi-kinase inhibitor, could modulate glucose metabolism, insulin/glucagon-like peptide-1 (GLP-1) pathways, and tau pathology in a streptozotocin (STZ)-induced rat model of AD. METHODS: Male rats (n = 5-8/group) received intracerebroventricular STZ to induce AD-like pathology and were subsequently treated with regorafenib for two weeks. Cognitive function was assessed using the Y-maze and novel object recognition (NOR) tests. Glucose metabolism was evaluated via 18F-FDG micro-PET imaging and glucose tolerance tests. Serum and hippocampal markers of insulin, GLP-1, and tau phosphorylation were measured. RESULTS: Regorafenib-treated rats exhibited significant improvement in recognition memory in the NOR test, while enhancement in spatial working memory in the Y-maze did not reach statistical significance. Regorafenib improved glucose metabolism in both the brain and periphery, as demonstrated by imaging and tolerance testing. Treatment significantly increased serum insulin and GLP-1 levels, and reduced hippocampal hyperphosphorylated tau, although hippocampal gene expression of insulin and GLP-1 signaling pathways remained unchanged. CONCLUSION: Regorafenib may provide neuroprotective benefits in AD by improving glucose metabolism and reducing tau pathology. These findings suggest regorafenib as a potential novel therapeutic strategy for AD, though further research is needed to confirm its efficacy, assess long-term outcomes, and elucidate underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulintau ProteinsAlzheimer DiseasePhenylurea CompoundsPyridinesGlucagon-Like Peptide 1GlucoseProtein Kinase InhibitorsAnimalsMaleStreptozocinDisease Models, AnimalSignal TransductionHippocampusRatsRats, Sprague-DawleyMaze LearningBlood Glucose

Stichwörter der Autor:innen

Alzheimer's diseaseGLP-1Glucose metabolismInsulinRegorafenib

Substanzen

Insulintau ProteinsPhenylurea CompoundsPyridinesStreptozocinregorafenibGlucagon-Like Peptide 1GlucoseBlood GlucoseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Neurobiology Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Neuroscience Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. nikzamirar@yahoo.com.
  • Neuroscience Research Center, Institute of Neuroscience and Cognition, Shahid Beheshti University of Medical Sciences, Tehran, Iran. l.dargahi@sbmu.ac.ir.

Förderung

  • The authors declare that this study was funded by the Research Affairs of Shahid Beheshti University of Medical Sciences.

Zitieren

APA

Salarinasab, S., Asgari Taei, A., Kaveh, N., Karima, S., Nikzamir, A., & Dargahi, L. (2026). Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04545-6

Vancouver

Salarinasab S, Asgari Taei A, Kaveh N, Karima S, Nikzamir A, Dargahi L. Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04545-6

BibTeX
@article{Salarinasab2026,
  author = {Salarinasab, Sadegh and Asgari Taei, Afsaneh and Kaveh, Neda and Karima, Saeed and Nikzamir, Abdolrahim and Dargahi, Leila},
  title = {Regorafenib modulates glucose metabolism, insulin/GLP-1 signaling, and tau pathology in an STZ-induced model of Alzheimer's disease},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04545-6}
}
Kostenlos starten →